Skip to content

Host DNA Methylation for Endometrial Cancer Screening

The Accuracy of Host DNA CDO1 and CELF4 Methylation for Endometrial Cancer Screening: a Multi-center Cohort Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05290415
Enrollment
10000
Registered
2022-03-22
Start date
2022-03-13
Completion date
2022-09-13
Last updated
2022-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer Screening, Cervical Cytology, Cohort Study, DNA Methylation, Endometrial Cancer, Liquid Biopsy

Brief summary

Based on the previous study of NCT04651738, we performed this trial to further confirm the accuracy of host DNA CDO1 and CELF4 methylation for endometrial cancer screening in a multi-center cohort. Thirteen hospitals, including Peking Union Medical College Hospital, would enroll eligible patients in this study. The cervical cytology of 3 ml will be collected for the detection of DNA CDO1 and CELF4 methylation, and the results will compared with the endometrial histological pathology, which is achieved after collection of cervical cytology, by surgeries including hysteroscopy, dilation and curettage, total hysterectomy and others. The methylation testing would be double-blinded in operators and analysts. The study will enroll at least 10,000 patients.

Interventions

DNA CDO1 and CELF4 methylation testing

Sponsors

Beijing Qiyuanjuhe Biotechnology Co., Ltd
CollaboratorUNKNOWN
Lei Li
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* With uterine and uterine cervix intact * Aged 18 years or older * With accessible histological results of endometrium * Signed an approved informed consents * With accessible cervical cytology before harvesting endometrial histology

Exclusion criteria

* Not meeting all of the inclusion criteria

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity of methylation testingOne weekSensitivity of methylation testing of cervical cytology compared with histology
Specificity of methylation testingOne weekSpecificity of methylation testing of cervical cytology compared with histology

Secondary

MeasureTime frameDescription
Positive predictive value of methylation testingOne weekPositive predictive value of methylation testing of cervical cytology compared with histology
Negative predictive value of methylation testingOne weekNegative predictive value of methylation testing of cervical cytology compared with histology

Countries

China

Contacts

Primary ContactLei Li, M.D.
lileigh@163.com10-139-1198-8831

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026